Phospho-Histone H3(Ser28) monoclonal antibodies specifically recognize histone H3 when phosphorylated at serine 28, a 15 kDa protein critical for chromatin structure and nucleosome assembly . Ser28 phosphorylation is mediated by MSK1 following activation by the MAP kinase pathway in response to stress signals (e.g., UV, EGF) or oncoproteins (e.g., c-Myc) . Unlike serine 10 phosphorylation (a well-established mitotic marker), Ser28 phosphorylation occurs exclusively during prophase and is absent in interphase cells . It correlates with chromosome condensation, RNA polymerase III regulation, and neoplastic transformation .
Flow cytometry: Used to assess mitotic arrest in nocodazole-treated HeLa cells, with optimal staining at 0.25–0.5 µg/test .
Immunofluorescence: Localizes to condensed chromosomes in prophase cells .
Comparative studies: Ser28 phosphorylation is less prevalent than Ser10 in untreated (0.5% vs. 4.75%) and nocodazole-treated HeLa cells (30.1% vs. 51.2%) .
Clinical relevance: Lower Ser28 levels in cancers suggest it is a secondary mitotic marker compared to Ser10 .
ELISA kits (e.g., Active Motif 53100) quantify Ser28 phosphorylation in acid-extracted histones, detecting as little as 156 ng of extract .
Paclitaxel-treated cells show elevated Ser28 phosphorylation due to mitotic arrest .
Fixation: Methanol or paraformaldehyde fixation preserves epitope integrity .
Permeabilization: 0.1% Triton X-100 enhances antibody access .
Controls: Include nocodazole-treated (positive) and thymidine-synchronized (negative) cells .
Lower sensitivity: Ser28 antibodies detect fewer mitotic cells than Ser10 antibodies, potentially due to delayed phosphorylation timing or epitope accessibility .
Species restrictions: Some clones (e.g., Cell Signaling #9713) are validated only for human, mouse, and hamster .
Validating antibody specificity requires rigorous controls and comparative analysis:
Positive Controls: Use nocodazole-treated cells (e.g., HeLa) to synchronize cells in mitosis, where H3S28 phosphorylation peaks . Confirm signal localization to mitotic chromatin.
Negative Controls: Include PTX-treated extracts (Active Motif ELISA) to exclude non-specific binding .
Cross-Reactivity Testing: Confirm no signal in samples where Ser28 phosphorylation is inhibited (e.g., MLTK-alpha knockdown cells) .
Western Blot vs. IHC/Flow Cytometry:
Advanced Consideration: Co-detection of H3S28p with H3K4me3 or H3.3 variants can distinguish transcriptional activation from mitotic events .
Fixation: Use 4% paraformaldehyde (10 min) followed by methanol permeabilization (30 min at -20°C) .
Antibody Titration: Start with 5 µL/test (0.25 µg) for HeLa cells; adjust for cell density (10⁵–10⁸ cells/test) .
Fluorophore Compatibility: Use eFluor® 660 (excitation 633–647 nm) to avoid spectral overlap with other markers .
Controls: Include isotype-matched antibodies and untreated samples to assess background noise.
Low Signal: Check fixation time (excessive fixation may mask epitopes).
High Background: Use blocking buffers (e.g., 2% BSA) and validate with H3S28p-negative cell lines .
Active Promoters: H3S28p is enriched in transcriptionally competent chromatin (S150 fraction) alongside H3K4me3 and H3.3 variants .
Nucleosome Destabilization: H3.3 phosphorylated at Ser28 forms labile nucleosomes, facilitating dynamic chromatin remodeling .
Transcriptional Activation: Linked to RNA Pol III recruitment, distinct from mitotic H3S10p .
Co-stain with H3.3 antibodies to assess variant-specific phosphorylation.
Use chromatin fractionation (e.g., S150 vs. S200) to isolate active vs. repressed regions .
| Stimulus | Kinase Involved | Inhibitor Test | Source |
|---|---|---|---|
| UVB/EGF | MLTK-alpha | MLTK-alpha siRNA | |
| c-Myc/c-Jun | MSK1 | H89 (PKA inhibitor) | |
| Tumor Promoters | MAPK cascade | PD98059 (MEK inhibitor) |
Use UVB (10 mJ/cm²) or EGF (100 ng/mL) to induce H3S28p in JB6 Cl41 cells; validate with MLTK-alpha knockdown .
Confirm pathway specificity by testing inhibitors (SB202190 for p38; ineffective for MLTK-alpha) .
Antibody Specificity:
Cell Cycle Synchronization:
Sample Preparation:
Phosphorylation Preference: H3.3 variants are preferentially phosphorylated at Ser28 in active chromatin .
Nucleosome Stability: H3.3-S28p nucleosomes are labile, aiding transcriptional activation .
Experimental Design:
Co-detect H3.3 and H3S28p via sequential IHC or ChIP-seq.
Use H3.3 knockout cells to assess variant-specific contributions.
Mitotic Context:
Transcriptional Context:
H3S28p in mitosis: Correlates with chromosome condensation .
H3S28p in transcription: Enriched at gene promoters with H3.3 and H3K4me3 .